(Q24186469)

English

Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

0 references

0 references

Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma (English)

0 references

multiple myeloma

1 reference

based on heuristic

inferred from title

4

0 references

5

0 references

3

0 references

1

object named as

Tim Hartmann

0 references

2

object named as

Kai Hübel

0 references

publication date

20 October 2015

0 references

Cochrane Database of Systematic Reviews

0 references

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: resul

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Improving stem cell mobilization strategies: future directions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Current status of stem cell mobilization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

The 2008 WHO classification of lymphomas: implications for clinical practice and translational research.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Mobilization strategies in hard‐to‐mobilize patients with lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

The evolving role of stem cell transplants in lymphomas

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Review of 1027 patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

High-dose chemotherapy followed by autologous stem cell transplantation for refractory/relapsed Hodgkin lymphoma patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Practical methods for incorporating summary time-to-event data into meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

21 January 2018

Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010615.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/14651858.CD010615.PUB2

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24186469&oldid=1742034207"